Development code · Small Molecule
MK-130
MK-130 is a development code for TNX-102 SL (cyclobenzaprine HCl sublingual), developed by Tonix Pharmaceuticals Holding Corp..
- Status
- Approved for Fibromyalgia
- Mechanism
- H1 receptor Antagonist
- Developer
- Tonix Pharmaceuticals Holding Corp.
Programs
- TNX-102 SL (cyclobenzaprine HCl sublingual) for FibromyalgiaApprovedApproved
- TNX-102 SL (cyclobenzaprine HCl sublingual) for Post-traumatic stress disorderDiscontinuedDiscontinued
- TNX-102 SL (cyclobenzaprine HCl sublingual) for Acute Stress DisorderPhase 2Recruiting
- TNX-102 SL (cyclobenzaprine HCl sublingual) for Major depressive disorderPhase 2Recruiting
Also known as
- TNX-102 SL
- TNX-102
- TONMYA
- cyclobenzaprine
- cyclobenzaprine hydrochloride
- 6202-23-9
- 303-53-7
View the full TNX-102 SL (cyclobenzaprine HCl sublingual) profile →